Comparing the current results to its competitors, Applied Therapeutics Inc reported Revenue increase in the 3 quarter 2025 by 719.67 % year on year. The sales growth was above Applied Therapeutics Inc 's competitors' average revenue growth of 11.36 %, achieved in the same quarter.
Applied Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 99.6 %
Applied Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the pharmaceutical industry, which is characterized by rapidly advancing technologies and intense competition. It faces potential competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Competitors may possess greater financial resources, established market presence, and expertise in areas such as research and development, manufacturing, clinical testing, regulatory approvals, reimbursement, and marketing. Competition also exists in recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. Smaller or early-stage companies may be significant competitors, particularly through collaborations with larger companies. Currently, no therapies are approved to treat Galactosemia.
December 18, 2024
In recent weeks, Applied Therapeutics, Inc. (NASDAQ: APLT) has become the focal point of investor scrutiny following the announcement of a class action lawsuit alleging that the company made materially false or misleading statements regarding its Phase III INSPIRE trial. This lawsuit, filed by Holzer and Holzer, LLC, comes at a time when the company is showcasing financial strength in some areas, sparking discussions among investors and industry observers alike.The class action lawsuit alleges that Applied Therapeutics concealed significant issues related to its Phase III clinical trial for its drug candidate, with particular focus on problems with electronic data capture and a dosing error during the dose-e...
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
Sources:
Applied Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Applied Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
